Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71243 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL71244 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL16908277 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL15508352 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL15508459 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL31137064 | 0.87 | CHRM2 (0.41) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL1006280 | 0.85 | CHRM2 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL1005463 | 0.85 | CHRM2 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL1005464 | 0.85 | CHRM2 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL17717511 | 0.85 | CHRM2 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019518-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3110820-B1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-10196390-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-2863914-B1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-10-03 | — | — | EP | disclosed |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-9630970-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-9630970-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| EP-1651622-B1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1651622-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651621-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| US-6924278-B2 | Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20050043310-A1 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005016896-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016897-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-03 | — | — | US | disclosed |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196390-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CHRM2 4803/4885CHRM1 4839/4885CHRM3 4729/4885 |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | TAC3, TACR1, SSTR5 | CHRM2 507/4885CHRM1 703/4885CHRM3 395/4885 |
| US-20050043310-A1 | Preparation of quinoxaline compounds | CCKAR, CCKBR, GIPR | CHRM2 1192/4885CHRM1 1440/4885CHRM3 977/4885 |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CHRM2 4803/4885CHRM1 4839/4885CHRM3 4729/4885 |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | TACR1, NPSR1, SSTR2 | CHRM2 183/4885CHRM1 167/4885CHRM3 231/4885 |
| US-20050038032-A1 | Quinoxaline compounds | CCKAR, CCKBR, GIPR | CHRM2 2459/4885CHRM1 3225/4885CHRM3 2630/4885 |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CHRM2 4803/4885CHRM1 4839/4885CHRM3 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.